Search

everythinglearnresearchcommunity

for

Search:↓

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

A specific group of immune and skin cells may cause chronic inflammation in atopic dermatitis.

Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

Combination therapy effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.

JAK1 inhibitors can help reduce itchiness in atopic dermatitis.

Omalizumab may cause temporary hair loss, especially in women aged 18-60.

Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.

A new type of alopecia areata, called the "confetti variant," causes small bald spots that often heal on their own in a few months.

TSLP affects atopic dermatitis by increasing sebum and reducing fat through IL-4/IL-13 signaling.

New treatments like JAK inhibitors offer hope for better alopecia areata management.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.

Alopecia areata gained more interest on social media than pattern hair loss, with TikTok showing more personal stories and YouTube offering higher quality educational content.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

People with atopic dermatitis have different skin bacteria, and targeting these bacteria might help treat the condition.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Follicular mucinosis can be an early sign of aggressive mycosis fungoides.

Benign follicular mucinosis involves immune cells attacking hair follicles.

Keratins 6, 16, and 17 increase in damaged or diseased skin and may help diagnose skin issues.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Stem cell vesicles reduced eczema symptoms in mice safely.

Targeted cytokine treatments may help with alopecia areata, but more research is needed.

Paeonol-loaded gels may help reduce inflammation and skin damage in atopic dermatitis.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Atopic dermatitis increases the risk of some autoimmune diseases.

Hair follicle stem cells reduced hair loss and inflammation in mice with a condition similar to human alopecia.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.